autologous vs. allogeneic
Stem cell procedures can use either (a) stem cells collected directly from the patient (“autologous”) or (b) stem cells developed from a non-patient donor of the same species (“allogeneic”). There are considerations to be aware of with either approach.
Most veterinary stem cell therapies today are autologous. These were the first approaches brought to market and have established a track record of efficacy and safety. The trend, however, is toward allogeneic treatments for some of the reasons discussed below. Note that studies are ongoing in this area and that no one study is conclusive. Furthermore, outcomes may vary due to differences in animal species, animal health, source of stem cell collection, laboratory techniques, and other factors.
Before deciding which path is best for your pet, consider the pros and cons of both approaches.
Academic Studies Discussing Age-Related Potency of Stem Cells
|Canine mesenchymal stem cells (MSCs): characterization in relation to donor age and adipose tissue-harvesting site. |
Guercio et al., Cell Biol. Int., 37: 789-798 (2013).
|Characterization of mesenchymal stem cells isolated from the adipose tissue of young and old dogs. |
Sancak et al., Ankara Üniv Vet Fak Derg, 63, 297-302 (2016).
|Comparison of proliferative and immunomodulatory potential of adipose-derived mesenchymal stem cells from young and geriatric cats. |
Zajic et al., Journal of Cutaneous Medicine and Surgery, 19(10):189-197 (2017).
WE ARE HERE TO DISCUSS YOUR OPTIONS.
Regenerative medicine is ever-changing as researchers and doctors learn more about the exciting possibilities of stem-cell-based therapies. JangoPet is committed to leveraging the current state of knowledge to provide customers and veterinarians cutting-edge therapeutic options to help animals affected by the degenerative effects of aging. Click below to explore our current services or to contact us directly.